Abstract library

41 results for "necrosis".
#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Dr. med. Georgi Atanasov
#77 Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors
Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse
Authors: Korse C M, Bonfrer J M, Taal B G, ...
#935 A Three Tier Grading System Based on Ki-67 Index, Mitotic Count and Necrosis with Cut-Offs Specifically Generated for Lung Neuroendocrine Tumors is Prognostically Effective and Accurate
Introduction: Lung neuroendocrine tumors are catalogued into four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neuroendocrine neoplasms is based on a Ki-67 index and has proved prognostically effective.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Professor Guido Rindi
Authors: Rindi G, Klersy C, Inzani F, ...
#2289 Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptor Expression in Patients with Neuroendocrine Neoplasia
Introduction: Targeting the death receptor pathway of apoptosis represents a promising approach for the development of novel cancer therapeutics. TNF-related TRAIL induces apoptosis upon binding to TRAIL receptors 1 and 2 (TRAIL-R1/DR4 and TRAIL-R2/DR5). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) have been reported to block TRAIL-mediated apoptosis upon overexpression. Specially agonists for the apoptosis-inducing TRAIL-R1 and TRAIL-R2 are currently tested in clinical trials.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr René Pschowski
Authors: Sättele R, Jann H, Fischer C, Pape U F, ...
Keywords: TRAIL, apoptosis, NENs
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#149 Giant adrenal tumor: a case report
Introduction: A gigantic adrenal tumor is a challenge regarding diagnosis before surgery and pathological exam, but also related to the surgical approach itself due to multiple risks.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Assoc. Professor Catalina Poiana
#1015 Pancreatic Neuroendocrine Tumors: Experience in a Spanish Reference Center
Introduction: Pancreatic neuroendocrine tumors (pNET) derived from the hormone-producing cells in the pancreas whose actual prevalence, natural history and optimal treatment raises controversy.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Cristina Tejera
#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET
#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: MD Anna La Salvia
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed